Work

Successful use of stapokibart as a biological therapy for allergic fungal rhinosinusitis: a case report

Year: 2026

Type: article

Abstract: Purpose: To present a rare, to our knowledge previously undescribed, case of successful AFRS management using stapokibart (CM310). Patients and methods: The laboratory, immunological, symptom scores and imaging datas before and after stapokibart treatment were evaluated to determine the effect of stapokibart on AFRS. Results: After four weeks of treatment, the patient showed significant clinical improvement, including a marked reduction in nasal polyp size and the near-complete return of normal olfaction. By week 16, lab tests confirmed a substantial drop in eosinophils and IgE, and a follow-up CT scan showed complete resolution of sinus inflammation. The patient reported high satisfaction due to a major improvement in quality of life. Conclusion: This pioneering case demonstrates that stapokibart, a novel anti-IL-4Rα antibody, is a promising and effective treatment for refractory AFRS, showing a rapid onset of action and sustained control of type 2 inflammation.

Source: Frontiers in Allergy

DOI: 10.3389/falgy.2025.1746033